Lucyna Antkiewicz-Michaluk

List of Publications by Year
in descending order

99 papers	2,005 citations	218381 26 h-index	315357 38 g-index
104 all docs	104 docs citations	104 times ranked	1667 citing authors

#	Article	IF	Citations
1	Psychiatric Disorders in Animal Models of Depression. , 2021, , 1-13.		0
2	1MeTIQ and olanzapine, despite their neurochemical impact, did not ameliorate performance in fear conditioning and social interaction tests in an MK-801 rat model of schizophrenia. Pharmacological Reports, 2021, 73, 490-505.	1.5	4
3	Pro-cognitive effect of 1MeTIQ on recognition memory in the ketamine model of schizophrenia in rats: the behavioural and neurochemical effects. Psychopharmacology, 2020, 237, 1577-1593.	1.5	11
4	1-Methyl-1,2,3,4-tetrahydroisoquinoline â€“ The toxicological research on an exo/endogenous amine with antidepressant-like activity â€“ In vivo, in vitro and in silico studies. Pharmacological Reports, 2019, 71, 1140-1146.	1.5	3
5	Resilient Phenotype in Chronic Mild Stress Paradigm Is Associated with Altered Expression Levels of miR-18a-5p and Serotonin 5-HT1a Receptor in Dorsal Part of the Hippocampus. Molecular Neurobiology, 2019, 56, 7680-7693.	1.9	17
6	Comparison of the effects of 1MeTIQ and olanzapine on performance in the elevated plus maze test and monoamine metabolism in the brain after ketamine treatment. Pharmacology Biochemistry and Behavior, 2019, 181, 17-27.	1.3	24
7	Novel antagonists of 5-HT6 and/or 5-HT7 receptors affect the brain monoamines metabolism and enhance the anti-immobility activity of different antidepressants in rats. Behavioural Brain Research, 2019, 359, 9-16.	1.2	6
8	Combined brain Fe, Cu, Zn and neurometabolite analysis â€“ a new methodology for unraveling the efficacy of transcranial direct current stimulation (tDCS) in appetite control. Metallomics, 2018, 10, 397-405.	1.0	6
9	Regulation of somatostatin receptor 2 in the context of antidepressant treatment response in chronic mild stress in rat. Psychopharmacology, 2018, 235, 2137-2149.	1.5	11
10	Multiple Administration of Endogenous Amines TIQ and 1MeTIQ Protects Against a 6-OHDA-Induced Essential Fall of Dopamine Release in the Rat Striatum: In Vivo Microdialysis Study. Neurotoxicity Research, 2018, 33, 523-531.	1.3	12
11	Changes in Monoaminergic Neurotransmission in an Animal Model of Osteoarthritis: The Role of Endocannabinoid Signaling. Frontiers in Molecular Neuroscience, 2018, 11, 466.	1.4	10
12	The Protective Effect of Repeated 1MeTIQ Administration on the Lactacystin-Induced Impairment of Dopamine Release and Decline in TH Level in the Rat Brain. Neurotoxicity Research, 2018, 34, 706-716.	1.3	3
13	Antidepressant-like effect of 1,2,3,4-tetrahydroisoquinoline and its methyl derivative in animal models of depression. Pharmacological Reports, 2017, 69, 566-574.	1.5	12
14	The mechanism of neuroprotective action of natural compounds. Pharmacological Reports, 2017, 69, 851-860.	1.5	68
15	Antidepressant-Like Effect of the Endogenous Neuroprotective Amine, 1MeTIQ in Clonidine-Induced Depression: Behavioral and Neurochemical Studies in Rats. Neurotoxicity Research, 2017, 32, 94-106.	1.3	13
16	The significance of rotational behavior and sensitivity of striatal dopamine receptors in hemiparkinsonian rats: A comparative study of lactacystin and 6-OHDA. Neuroscience, 2017, 340, 308-318.	1.1	13
17	Repeated Transcranial Direct Current Stimulation Induces Behavioral, Metabolic and Neurochemical Effects in Rats on High-Calorie Diet. Frontiers in Behavioral Neuroscience, 2017, 11, 262.	1.0	8
18	The adenosinergic system is involved in sensitization to morphine withdrawal signs in ratsâ€”neurochemical and molecular basis in dopaminergic system. Psychopharmacology, 2016, 233, 2383-2397.	1.5	7

#	Article	IF	Citations
19	Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT6 partial agonist in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 839-849.	1.4	16
20	The impact of 1MeTIQ on the dopaminergic system function in the 6-OHDA model of Parkinsonâ€™s disease. Pharmacological Reports, 2016, 68, 1205-1213.	1.5	11
21	Comparison of the Effects of Acute and Chronic Administration of Tetrahydroisoquinoline Amines on the In Vivo Dopamine Release: A Microdialysis Study in the Rat Striatum. Neurotoxicity Research, 2016, 30, 648-657.	1.3	7
22	The Effect of Chronic Mild Stress and Imipramine on the Markers of Oxidative Stress and Antioxidant System in Rat Liver. Neurotoxicity Research, 2016, 30, 173-184.	1.3	30
23	Acute treatment with doxorubicin induced neurochemical impairment of the function of dopamine system in rat brain structures. Pharmacological Reports, 2016, 68, 627-630.	1.5	16
24	Neuroprotective Effect of the Endogenous Amine 1MeTIQ in an Animal Model of Parkinsonâ€™s Disease. Neurotoxicity Research, 2016, 29, 351-363.	1.3	11
25	Salsolinol, an Endogenous Compound Triggers a Two-Phase Opposing Action in the Central Nervous System. Neurotoxicity Research, 2015, 27, 300-313.	1.3	19
26	Chronic Salsolinol Administration Prevents the Behavioral and Neurochemical Effects of l-DOPA in Rats. Neurotoxicity Research, 2015, 27, 399-410.	1.3	3
27	Withdrawal from repeated administration of a low dose of reserpine induced opposing adaptive changes in the noradrenaline and serotonin system function: A behavioral and neurochemical ex vivo and in vivo studies in the rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 57, 146-154.	2.5	9
28	1-Methyl-1,2,3,4-Tetrahydroisoquinoline, an Endogenous Amine with Unexpected Mechanism of Action: New Vistas of Therapeutic Application. Neurotoxicity Research, 2014, 25, 1-12.	1.3	37
29	1MeTIQ Provides Protection Against AÎ²-Induced Reduction of Surface Expression of Synaptic Proteins and Inhibits H2O2-Induced Oxidative Stress in Primary Hippocampal Neurons. Neurotoxicity Research, 2014, 25, 348-357.	1.3	11
30	1-Methyl-1,2,3,4-tetrahydroisoquinoline, an Endogenous Neuroprotectant and MAO Inhibitor with Antidepressant-Like Properties in the Rat. Neurotoxicity Research, 2014, 25, 323-334.	1.3	16
31	Concentration-Dependent Opposite Effects of 1-Benzyl-1,2,3,4-tetrahydroisoquinoline on Markers of Apoptosis: In Vitro and Ex Vivo Studies. Neurotoxicity Research, 2014, 25, 90-99.	1.3	13
32	Antidepressant-like Effect of Tetrahydroisoquinoline Amines in the Animal Model of Depressive Disorder Induced by Repeated Administration of a Low Dose of Reserpine: Behavioral and Neurochemical Studies in the Rat. Neurotoxicity Research, 2014, 26, 85-98.	1.3	70
33	1-Benzyl-1,2,3,4-tetrahydroisoquinoline, an Endogenous Neurotoxic Compound, Disturbs the Behavioral and Biochemical Effects of l-DOPA: In Vivo and Ex Vivo Studies in the Rat. Neurotoxicity Research, 2014, 26, 240-254.	1.3	7
34	1,2,3,4-Tetrahydroisoquinoline produces an antidepressant-like effect in the forced swim test and chronic mild stress model of depression in the rat: Neurochemical correlates. European Journal of Pharmacology, 2014, 729, 107-115.	1.7	15
35	Effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline on the protective action of various antiepileptic drugs in the maximal electroshock-induced seizure model: a type II isobolographic analysis. Journal of Neural Transmission, 2013, 120, 1651-1663.	1.4	3
36	Antidepressant-like activity of the endogenous amine, 1-methyl-1,2,3,4-tetrahydroisoquinoline in the behavioral despair test in the rat, and its neurochemical correlates: A comparison with the classical antidepressant, imipramine. European Journal of Pharmacology, 2013, 700, 110-117.	1.7	21

#	Article	IF	Citations
37	Anticonvulsant evaluation of aminoalkanol derivatives of 2- and 4-methylxanthone. Bioorganic and Medicinal Chemistry, 2013, 21, 1190-1198.	1.4	17
38	Chronic impairment of the vagus nerve function leads to inhibition of dopamine but not serotonin neurons in rat brain structures. Pharmacological Reports, 2012, 64, 1359-1367.	1.5	29
39	Comparative behavioral and neurochemical studies of R- and S-1-methyl-1,2,3,4-tetrahydroisoquinoline stereoisomers in the rat. Pharmacological Reports, 2012, 64, 857-869.	1.5	8
40	1-Methyl-1,2,3,4-Tetrahydroisoquinoline: A Potent Neuroprotecting Agent. , 2012, , 45-56.		2
41	Isoquinolines as Neurotoxins: Action and Molecular Mechanism. , 2012, , 31-43.		1
42	1-Methyl-1,2,3,4-Tetrahydroisoquinoline and Addiction: Experimental Studies. , 2012, , 57-74.		0
43	Effects of the noradrenergic neurotoxin DSP-4 on the expression of Î±1-adrenoceptor subtypes after antidepressant treatment. Pharmacological Reports, 2011, 63, 1349-1358.	1.5	10
44	Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats. Neurochemistry International, 2011, 58, 839-849.	1.9	34
45	5-Hydroxytryptamine-like properties of m-chlorophenylpiperazine: comparison with quipazine. Journal of Pharmacy and Pharmacology, 2011, 32, 220-222.	1.2	46
46	Both Stereoselective (R)- and (S)-1-Methyl-1,2,3,4-tetrahydroisoquinoline Enantiomers Protect Striatal Terminals Against Rotenone-Induced Suppression of Dopamine Release. Neurotoxicity Research, 2011, 20, 134-149.	1.3	7
47	Interactions of 1-methyl-1,2,3,4-tetrahydroisoquinoline with lamotrigine, oxcarbazepine, pregabalin, and topiramate in the mouse maximal electroshock-induced seizure model: A type I isobolographic analysis. Epilepsy Research, 2010, 89, 207-219.	0.8	12
48	1-Methyl-1,2,3,4-tetrahydroisoquinoline and established uncompetitive NMDA receptor antagonists induce tolerance to excitotoxicity. Pharmacological Reports, 2010, 62, 1041-1050.	1.5	14
49	Important role of 3-methoxytyramine in the inhibition of cocaine sensitization by 1-methyl-1,2,3,4-tetrahydroisoquinoline: an in vivo microdialysis study. Pharmacological Reports, 2010, 62, 983-997.	1.5	14
50	Isobolographic analysis of interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and four conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. European Journal of Pharmacology, 2009, 602, 298-305.	1.7	39
51	1-Benzyl-1,2,3,4-Tetrahydroisoquinoline, an Endogenous Parkinsonism-Inducing Toxin, Strongly Potentiates MAO-Dependent Dopamine Oxidation and Impairs Dopamine Release: Ex vivo and In vivo Neurochemical Studies. Neurotoxicity Research, 2009, 15, 15-23.	1.3	22
52	1-Methyl-1,2,3,4-tetrahydroisoquinoline Antagonizes a Rise in Brain Dopamine Metabolism, Glutamate Release in Frontal Cortex and Locomotor Hyperactivity Produced by MK-801 but not the Disruptions of Prepulse Inhibition, and Impairment of Working Memory in Rat. Neurotoxicity Research, 2009, 16, 390-407.	1.3	32
53	Anticonvulsant activity of some xanthone derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 7234-7244.	1.4	34
54	3-Methoxytyramine, an extraneuronal dopamine metabolite plays a physiological role in the brain as an inhibitory regulator of catecholaminergic activity. European Journal of Pharmacology, 2008, 599, 32-35.	1.7	25

#	Article	IF	Citations
55	1-Methyl-1,2,3,4-tetrahydroisoquinoline enhances the anticonvulsant action of carbamazepine and valproate in the mouse maximal electroshock seizure model. Neuropharmacology, 2006, 50, 133-142.	2.0	18
56	The mechanism of 1,2,3,4-tetrahydroisoquinolines neuroprotection: the importance of free radicals scavenging properties and inhibition of glutamate-induced excitotoxicity. Journal of Neurochemistry, 2006, 97, 846-856.	2.1	50
57	Conditioned rewarding stimulus associated with cocaine self-administration reverses the depression of catecholamine brain systems following cocaine withdrawal in rats. International Journal of Neuropsychopharmacology, 2006, 9, 37.	1.0	4
58	Nicotine potentiates imipramine-induced effects on catecholamine metabolism: possible relation to antidepressant activity. Pharmacological Reports, 2006, 58, 836-45.	1.5	0
59	Nicotine produces antidepressant-like actions: Behavioral and neurochemical evidence. European Journal of Pharmacology, 2005, 515, 128-133.	1.7	15
60	Antidepressant-like effect of the selective 5-HT1B receptor agonist CP 94253: A possible mechanism of action. European Journal of Pharmacology, 2005, 516, 46-50.	1.7	36
61	Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. International Journal of Neuropsychopharmacology, 2004, 7, 155-163.	1.0	50
62	Effect of 1,2,3,4,-tetrahydroisoquinoline administration under conditions of CYP2D inhibition on dopamine metabolism, level of tyrosine hydroxylase protein and the binding of [3H]GBR 12,935 to dopamine transporter in the rat nigrostriatal, dopaminergic system. Brain Research, 2004, 1009, 67-81.	1.1	13
63	Inhibition of rodent brain monoamine oxidase and tyrosine hydroxylase by endogenous compounds - 1,2,3,4-tetrahydro-isoquinoline alkaloids. Polish Journal of Pharmacology, 2004, 56, 727-34.	0.3	35
64	A possible physiological role for cerebral tetrahydroisoquinolines. Neurotoxicity Research, 2003, 5, 147-155.	1.3	41
65	1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain. European Journal of Pharmacology, 2003, 466, 263-269.	1.7	41
66	Synthesis and Pharmacological Activity of New Carbonyl Derivatives of 1-Aryl-2-iminoimidazolidine. Part 3. Synthesis and Pharmacological Activity of 1-Aryl-5,6(1H)dioxo-2,3-dihydroimidazo[1,2-a]imidazoles.. ChemInform, 2003, 34, no.	0.1	1
67	Synthesis and Pharmacological Activity of New Carbonyl Derivatives of 1-Aryl-2-iminoimidazolidine. Part 2. Synthesis and Pharmacological Activity of 1,6-Diaryl-5,7(1H)dioxo-2,3-dihydroimidazo[1,2-a][1,3,5]triazines.. ChemInform, 2003, 34, no.	0.1	1
68	Behavioural and biochemical studies of citalopram and WAY 100635 in rat chronic mild stress model. Pharmacology Biochemistry and Behavior, 2002, 72, 465-474.	1.3	50
69	Synthesis, antiarrhythmic, and antihypertensive effects of novel 1-substituted pyrrolidin-2-one and pyrrolidine derivatives with adrenolytic activity. European Journal of Medicinal Chemistry, 2002, 37, 183-195.	2.6	39
70	Synthesis and pharmacological activity of new carbonyl derivatives of 1-aryl-2-iminoimidazolidine. European Journal of Medicinal Chemistry, 2002, 37, 845-853.	2.6	27
71	Synthesis and pharmacological activity of new carbonyl derivatives of 1-aryl-2-iminoimidazolidine. European Journal of Medicinal Chemistry, 2002, 37, 761-772.	2.6	27
72	Role of noradrenergic system in the mechanism of action of endogenous neurotoxin 1,2,3,4-tetrahydroisoquinoline: biochemical and functional studies. Polish Journal of Pharmacology, 2002, 54, 19-25.	0.3	5

#	Article	IF	Citations
73	Endogenous risk factors in Parkinson's disease: dopamine and tetrahydroisoquinolines. Polish Journal of Pharmacology, 2002, 54, 567-72.	0.3	20
74	Synthesis and pharmacological activity of new carbonyl derivatives of 1-aryl-2-iminoimidazolidine Part 1. Synthesis and pharmacological activity of chain derivatives of 1-aryl-2-iminoimidazolidine containing urea moiety. European Journal of Medicinal Chemistry, 2001, 36, 783-797.	2.6	23
75	Different action on dopamine catabolic pathways of two endogenous 1,2,3,4-tetrahydroisoquinolines with similar antidopaminergic properties. Journal of Neurochemistry, 2001, 78, 100-108.	2.1	79
76	Antidopaminergic Effects of Putative Endogenous MPTP-Like Agents: 1,2,3,4-Tetrahydroisoquinoline and 1-Methyl-6,7-Dihydroxy-l,2,3,4-Tetrahydroisoquinoline. , 2000, , 105-110.		0
77	The Ca2+ Channel Blockade Changes the Behavioral and Biochemical Effects of Immobilization Stress. Neuropsychopharmacology, 1999, 20, 248-254.	2.8	19
78	Synthesis, Physicochemical Properties, Anticonvulsant Activities, and GABA-ergic and Voltage-sensitive Calcium Channel Receptor Affinities of Î±-SubstitutedN-Benzylamides of Î³-Hydroxybutyric Acid Part 4: Search for New Anticonvulsant Compounds. Archiv Der Pharmazie, 1999, 332, 167-174.	2.1	9
79	Plasticity of extrapyramidal dopamine system in Parkinson's disease - A postmortem study. Neuroscience Research Communications, 1999, 25, 97-109.	0.2	5
80	Effects of various Ca2+ channel antagonists on morphine analgesia, tolerance and dependence, and on blood pressure in the rat. European Journal of Pharmacology, 1998, 352, 189-197.	1.7	68
81	Ca2+ channel blockade prevents lysergic acid diethylamide-induced changes in dopamine and serotonin metabolism. European Journal of Pharmacology, 1997, 332, 9-14.	1.7	13
82	Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: advantage of a new high-performance liquid chromatography methodology. Biological Psychiatry, 1997, 42, 514-518.	0.7	35
83	Search for New Antiarrhythmic and Hypotensive Compounds. Synthesis, Antiarrhythmic, Antihypertensive, and Î±-Adrenoceptor Blocking Activity of Novel 1-[(2-Hydroxy-3-amino)]-propylpyrrolidin-2-one Derivatives. Archiv Der Pharmazie, 1997, 330, 225-231.	2.1	16
84	Different effects of chronic administration of haloperidol and pimozide on dopamine metabolism in the rat brain. European Journal of Pharmacology, 1996, 313, 181-186.	1.7	10
85	Differences in effects of Ca 2+ channel antagonists on dopamine metabolism in the limbic and extrapyramidal dopaminergic structures. Psychopharmacology, 1996, 128, 39-44.	1.5	3
86	Differences between haloperidol- and pimozide-induced withdrawal syndrome: a role for Ca2+ channels. European Journal of Pharmacology, 1995, 294, 459-467.	1.7	13
87	Differential involvement of voltage-dependent calcium channels in apomorphine-induced hypermotility and stereotypy. Psychopharmacology, 1994, 113, 555-560.	1.5	7
88	Purification of a novel DBI processing product, DBI39â€“75, and characterization of its binding site in rat brain. Regulatory Peptides, 1994, 50, 29-35.	1.9	19
89	Modification of effects of chronic electroconvulsive shock by voltage-dependent Ca2+ channel blockade with nifedipine. European Journal of Pharmacology, 1994, 254, 9-16.	1.7	14
90	Reduction of morphine dependence and potentiation of analgesia by chronic co-administration of nifedipine. Psychopharmacology, 1993, 111, 457-464.	1.5	55

#	Article	IF	Citations
91	Serotonin, dopamine, noradrenaline and their metabolites: Levels in the brain of the house cricket (Acheta domesticus L.) during a 24-hour period and after administration of quipazineâ€"a 5-HT2 receptor agonist. Comparative Biochemistry and Physiology Part C: Comparative Pharmacology, 1991, 100, 365-371.	0.2	3
92	Role of calcium channels in effects of antidepressant drugs on responsiveness to pain. Psychopharmacology, 1991, 105, 269-274.	1.5	45
93	Effect of repetitive electroconvulsive treatment on sensitivity to pain and on [3H]nitrendipine binding sites in cortical and hippocampal membranes. Psychopharmacology, 1990, 101, 240-243.	1.5	20
94	Cortical dihydropyridine binding sites and a behavioral syndrome in morphine-abstinent rats. European Journal of Pharmacology, 1990, 180, 129-135.	1.7	36
95	The effect of chronic imipramine and electroconvulsive shock treatment on [3H]DADLE binding to cortical membranes of rats pretreated with chronic reserpine or 6-hydroxydopamine. Pharmacology Biochemistry and Behavior, 1987, 26, 203-206.	1.3	7
96	Effects of Chronically Administered Antidepressants and Electroconvulsive Treatment on Cerebral Neurotransmitter Receptors in Rodents with â€˜Model Depressionâ€™. Novartis Foundation Symposium, 1986, 123, 234-245.	1.2	3
97	Increase in rat cortical [3H]naloxone binding site density after chronic administration of antidepressant agents. European Journal of Pharmacology, 1984, 102, 179-181.	1.7	32
98	Chronic administration of antidepressant drugs increases the density of cortical [3H]prazosin binding sites in the rat. Brain Research, 1984, 310, 360-362.	1.1	74
99	Dopamine receptors in the striatum and limbic system of various strains of mice: Relation to differences in responses to apomorphine. Pharmacology Biochemistry and Behavior, 1982, 17, 1115-1118.	1.3	33